 The aim of the study is to investigate the efficacy of navigated individualized αTMS in treatment-resistant patients with schizophrenia. Approximately fifty patients with DSM-IV schizophrenia will be enrolled in this randomized, double-blind, sham-controlled study. The patients will receive 13 - 15 session of αTMS to the left dorsolateral prefrontal cortex DLPFC, as adjunctive therapy, for 3 weeks. We assess patients via the Positive and Negative Syndrome Scale PANSS, Clinical Global Impression CGI and neurocognitive test battery at baseline, 5 days after and 3 months after treatment. Serum and plasma levels of brain derived neurotrophic factor BDNF are assayed at pre and post treatment weeks. 